Kevin R. Sayer, Executive Chair and Director of DexCom Inc (NASDAQ:DXCM), filed a Form 4 on August 24, 2026, reporting the sale of common stock on August 20, 2026, pursuant to a pre-established 10b5-1 trading plan.

Key Highlights

  • Three sale transactions: Sayer disposed of 19,308 shares at a weighted average price of $89.706, 7,351 shares at a weighted average price of $90.7811, and 97 shares at $91.41, all on August 20, 2026.
  • Total shares sold: 26,756 shares of DexCom common stock were disposed of across the three transactions.
  • Remaining beneficial ownership: Following the sales, Sayer directly beneficially owned 302,214 shares of common stock, according to the filing.
  • Unvested RSUs included: The post-transaction ownership figure includes 106,972 unvested restricted stock units from grants made on March 8, 2024, March 8, 2025, and March 8, 2026.
  • 10b5-1 plan: The filing states Sayer adopted the trading plan on February 18, 2026, to allow "the orderly disposition of shares owned by Mr. Sayer."
  • Multi-trade execution: The first transaction was executed at prices ranging from $89.275 to $90.25, and the second at prices ranging from $90.32 to $91.19, with weighted averages reported.

DexCom Executive Chair's August 2026 Share Dispositions Under Pre-Planned Trading Program

According to the Form 4 filed with the SEC on August 24, 2026, Kevin R. Sayer, identified as Executive Chair and Director of DexCom Inc, sold a combined 26,756 shares of the company's common stock on August 20, 2026. All three transactions are designated with transaction code "S" (sale) and are reported as directly owned shares disposed of. The filing indicates a checkbox confirming the transactions were made pursuant to a Rule 10b5-1(c) plan.

The filing discloses that Sayer adopted the 10b5-1 plan on February 18, 2026. The two larger transactions were each executed across multiple trades: the 19,308-share sale at prices ranging from $89.275 to $90.25 (weighted average $89.706), and the 7,351-share sale at prices ranging from $90.32 to $91.19 (weighted average $90.7811). The filing notes that full information regarding individual trade prices and share counts is available upon request to the SEC staff, the issuer, or a security holder.

After the reported sales, Sayer's direct beneficial ownership stood at 302,214 shares, as disclosed in the filing. That total includes 106,972 unvested restricted stock units: 32,749 granted March 8, 2026 vesting through March 8, 2027; 56,993 granted March 8, 2025 vesting through March 8, 2028; and 17,230 granted March 8, 2024 vesting through March 8, 2027. The form was signed by Jereme M. Sylvain as Attorney-in-Fact for Kevin R. Sayer on August 24, 2026.

What Was Disclosed

The filing reports three sales of DexCom common stock by Executive Chair Kevin R. Sayer on August 20, 2026, totaling 26,756 shares at weighted average prices between $89.706 and $91.41, all executed under a 10b5-1 plan adopted February 18, 2026.